RAPP vs. RXRX, OCUL, IRON, CGON, BLTE, MESO, ADPT, SRPT, ANIP, and ARQT
Should you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), Disc Medicine (IRON), CG Oncology (CGON), Belite Bio (BLTE), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), ANI Pharmaceuticals (ANIP), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.
Rapport Therapeutics vs. Its Competitors
Rapport Therapeutics (NASDAQ:RAPP) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.
Rapport Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Rapport Therapeutics' return on equity of -29.99% beat Recursion Pharmaceuticals' return on equity.
In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 3 mentions for Recursion Pharmaceuticals and 1 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.08 beat Recursion Pharmaceuticals' score of 0.91 indicating that Rapport Therapeutics is being referred to more favorably in the media.
Rapport Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rapport Therapeutics currently has a consensus target price of $29.50, suggesting a potential upside of 96.14%. Recursion Pharmaceuticals has a consensus target price of $7.25, suggesting a potential upside of 56.59%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rapport Therapeutics is more favorable than Recursion Pharmaceuticals.
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 13.6% of Rapport Therapeutics shares are held by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Rapport Therapeutics has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Summary
Rapport Therapeutics beats Recursion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Rapport Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rapport Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RAPP) was last updated on 9/4/2025 by MarketBeat.com Staff
